Strategic Partnership Allows for Marketing and Distributing Neauvia North America’s Plasma IQ

Neauvia North America’s Plasma IQ, the first Class 2 FDA cleared plasma energy device will be marketed and distributed throughout North America, the result of a strategic partnership between Suneva Medical and Neauvia.

Plasma IQ is the latest advancement in aesthetics that delivers focused, controlled plasma energy to safely and effectively create microinjuries on the skin, renewing and restoring it.

“This is an exciting partnership as Suneva Medical is well positioned to offer a unique technology to a number of providers looking for new aesthetic treatments that are safe and effective,” said Sean Wilson, CEO of Neauvia North America.

“We are looking forward to welcoming Plasma IQ to our ever-expanding portfolio of facial regenerative aesthetics products,” said Pat Altavilla, CEO of Suneva Medical.  “With the introduction of Plasma IQ, we continue our commitment to providing proven and validated innovations for aesthetic providers and their patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version